Acadia Pharmaceuticals and Stoke Therapeutics are teaming up to develop and commercialize new RNA-based therapies — using Stoke’s proprietary research platform, TANGO — for the potential treatment of Rett syndrome. As part of the collaboration, Stoke will receive a $60 million upfront payment from Acadia. “Stoke’s RNA-based approach to upregulating healthy proteins offers very exciting new possibilities for the treatment of rare, neurodevelopmental diseases like Rett syndrome,” Steve Davis, CEO of Acadia, said in a…

You must be logged in to read/download the full post.